In them, the overexpression of apoCIII slows down the removal of TG from lipoproteins, decreasing their affinity for lipoprotein lipase (LPL) and reducing the uptake of VLDL and chylomicrons via the hepatic receptor (10-, 12), leading to hypertriglyceridemia in the animals. Here, APOC3 is linked to hypertriglyceridemia.